Redeye provides an update following Senzime’s Q3 2025 report. Sales came in a bit lower than we expected; however, looking at the bigger picture, Senzime’s development is in the right direction and the outlook remains strong. In this update, we make only minor adjustments to our estimates, leaving our fair value range unchanged.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/